(CVRX) CVRx - Ratings and Ratios
Neuromodulation Device, Heart Failure Treatment, Medical Device
CVRX EPS (Earnings per Share)
CVRX Revenue
Description: CVRX CVRx
CVRx Inc (NASDAQ:CVRX) is a commercial-stage medical device company that develops and commercializes neuromodulation solutions for cardiovascular diseases. The companys flagship product, Barostim, is a neuromodulation device that alleviates symptoms for heart failure patients by delivering electrical pulses to baroreceptors, which are sensors that detect changes in blood pressure.
From a business perspective, CVRx has a diversified sales channel, including a direct sales force, sales agents, and independent distributors, allowing it to reach a broader customer base. With a presence in the US, Germany, and internationally, the company is well-positioned to capitalize on the growing demand for innovative cardiovascular treatments.
To evaluate CVRxs performance, key performance indicators (KPIs) such as revenue growth, gross margin, and operating expenses as a percentage of revenue are crucial. Given the companys commercial-stage status, Id expect to see increasing revenue and potentially improving gross margins as the business scales. Additionally, metrics like customer acquisition cost and patient enrollment rates for Barostim could provide insight into the companys sales efficiency and product adoption.
From a financial perspective, CVRxs market capitalization is approximately $181.47 million, indicating a relatively small-cap stock. The absence of a P/E ratio suggests that the company is not yet profitable, which is consistent with its commercial-stage status and potential for future growth. Return on Equity (RoE) is -79.04%, highlighting the companys current net losses. To gauge the companys path to profitability, monitoring cash burn rate, operating expense management, and potential future revenue streams will be essential.
CVRX Stock Overview
| Market Cap in USD | 208m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2021-06-30 |
CVRX Stock Ratings
| Growth Rating | -32.0% |
| Fundamental | 24.9% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -24.2% |
| Analyst Rating | 4.57 of 5 |
CVRX Dividends
Currently no dividends paidCVRX Growth Ratios
| Growth Correlation 3m | 54.1% |
| Growth Correlation 12m | -59.2% |
| Growth Correlation 5y | -12.7% |
| CAGR 5y | -5.82% |
| CAGR/Max DD 3y | -0.07 |
| CAGR/Mean DD 3y | -0.12 |
| Sharpe Ratio 12m | -0.04 |
| Alpha | -24.94 |
| Beta | 0.368 |
| Volatility | 88.98% |
| Current Volume | 294.2k |
| Average Volume 20d | 136.1k |
| Stop Loss | 6.4 (-7.5%) |
| Signal | -2.29 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-52.3m TTM) > 0 and > 6% of Revenue (6% = 3.28m TTM) |
| FCFTA -0.34 (>2.0%) and ΔFCFTA 7.39pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 194.8% (prev 186.7%; Δ 8.12pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.33 (>3.0%) and CFO -39.1m > Net Income -52.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 11.99 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (26.1m) change vs 12m ago 20.54% (target <= -2.0% for YES) |
| Gross Margin 84.04% (prev 83.79%; Δ 0.26pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 50.71% (prev 46.25%; Δ 4.46pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -8.67 (EBITDA TTM -46.2m / Interest Expense TTM 5.41m) >= 6 (WARN >= 3) |
Altman Z'' -22.15
| (A) 0.89 = (Total Current Assets 116.1m - Total Current Liabilities 9.69m) / Total Assets 119.6m |
| (B) -4.73 = Retained Earnings (Balance) -565.8m / Total Assets 119.6m |
| warn (B) unusual magnitude: -4.73 — check mapping/units |
| (C) -0.43 = EBIT TTM -46.9m / Avg Total Assets 107.8m |
| (D) -9.18 = Book Value of Equity -565.8m / Total Liabilities 61.6m |
| Total Rating: -22.15 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 24.93
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -24.91% = -5.0 |
| 3. FCF Margin -74.11% = -7.50 |
| 4. Debt/Equity 0.86 = 2.15 |
| 5. Debt/Ebitda -1.08 = -2.50 |
| 6. ROIC - WACC -47.10% = -12.50 |
| 7. RoE -79.31% = -2.50 |
| 8. Rev. Trend 92.65% = 6.95 |
| 9. EPS Trend -13.21% = -0.66 |
What is the price of CVRX shares?
Over the past week, the price has changed by -12.96%, over one month by -1.56%, over three months by +17.69% and over the past year by -9.90%.
Is CVRx a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CVRX is around 6.22 USD . This means that CVRX is currently overvalued and has a potential downside of -10.12%.
Is CVRX a buy, sell or hold?
- Strong Buy: 5
- Buy: 1
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CVRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 10.8 | 56.5% |
| Analysts Target Price | 10.8 | 56.5% |
| ValueRay Target Price | 6.8 | -1.7% |
Last update: 2025-09-10 04:35
CVRX Fundamental Data Overview
CCE Cash And Equivalents = 95.0m USD (Cash And Short Term Investments, last quarter)
P/S = 3.8042
P/B = 3.5778
Beta = 1.224
Revenue TTM = 54.7m USD
EBIT TTM = -46.9m USD
EBITDA TTM = -46.2m USD
Long Term Debt = 49.4m USD (from longTermDebt, last quarter)
Short Term Debt = 333.0k USD (from shortTermDebt, last quarter)
Debt = 49.7m USD (Calculated: Short Term 333.0k + Long Term 49.4m)
Net Debt = -44.5m USD (from netDebt column, last quarter)
Enterprise Value = 162.6m USD (207.9m + Debt 49.7m - CCE 95.0m)
Interest Coverage Ratio = -8.67 (Ebit TTM -46.9m / Interest Expense TTM 5.41m)
FCF Yield = -24.91% (FCF TTM -40.5m / Enterprise Value 162.6m)
FCF Margin = -74.11% (FCF TTM -40.5m / Revenue TTM 54.7m)
Net Margin = -95.61% (Net Income TTM -52.3m / Revenue TTM 54.7m)
Gross Margin = 84.04% ((Revenue TTM 54.7m - Cost of Revenue TTM 8.72m) / Revenue TTM)
Tobins Q-Ratio = -0.29 (set to none) (Enterprise Value 162.6m / Book Value Of Equity -565.8m)
Interest Expense / Debt = 2.96% (Interest Expense 1.47m / Debt 49.7m)
Taxrate = 21.0% (US default)
NOPAT = -46.9m (EBIT -46.9m, no tax applied on loss)
Current Ratio = 11.99 (Total Current Assets 116.1m / Total Current Liabilities 9.69m)
Debt / Equity = 0.86 (Debt 49.7m / last Quarter total Stockholder Equity 57.9m)
Debt / EBITDA = -1.08 (Net Debt -44.5m / EBITDA -46.2m)
Debt / FCF = -1.23 (Debt 49.7m / FCF TTM -40.5m)
Total Stockholder Equity = 65.9m (last 4 quarters mean)
RoA = -43.70% (Net Income -52.3m, Total Assets 119.6m )
RoE = -79.31% (Net Income TTM -52.3m / Total Stockholder Equity 65.9m)
RoCE = -40.66% (Ebit -46.9m / (Equity 65.9m + L.T.Debt 49.4m))
RoIC = -40.70% (NOPAT -46.9m / Invested Capital 115.2m)
WACC = 6.40% (E(207.9m)/V(257.6m) * Re(7.37%)) + (D(49.7m)/V(257.6m) * Rd(2.96%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 96.97 | Cagr: 2.17%
Discount Rate = 7.37% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -40.5m)
EPS Correlation: -13.21 | EPS CAGR: -6.17% | SUE: -0.25 | # QB: False
Revenue Correlation: 92.65 | Revenue CAGR: 33.13%
Additional Sources for CVRX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle